Combining automated patch clamp with optogenetics enables selective recording of DRG neurons subtypes

This paper presents a novel method combining automated patch clamp recording with optogenetic stimulation to selectively identify and record from specific NaV1.8 and TRPV1-expressing dorsal root ganglion neuron subtypes, thereby enhancing the study of nociception and the development of targeted analgesics.

The Gist

Imagine your body's nervous system as a massive, bustling city. The Dorsal Root Ganglia (DRG) are like the city's main train stations, where thousands of different types of sensory "commuters" (neurons) gather before heading to the brain. Some commuters carry messages about a gentle touch, others about burning heat, and some about sharp pain.

The problem is that these commuters all look and act very similarly when you try to study them. It's like trying to sort a crowd of people wearing identical gray coats just by looking at them; you can't tell who is a doctor, who is a chef, and who is a firefighter. This makes it incredibly hard for scientists to figure out which specific "commuter" is responsible for pain, and therefore, hard to design drugs that stop the pain without shutting down the whole city.

The Old Way: The Manual Sort

Traditionally, scientists studied these neurons one by one using a method called "patch clamp." Think of this as a highly skilled librarian trying to sort books by hand, one at a time. It's slow, tedious, and you can only handle a few books before you get tired. If you want to test a new painkiller, you'd have to wait days or weeks to test it on enough neurons to be sure it works.

The New Way: The High-Speed Train with a GPS

This paper introduces a brilliant new method that combines two powerful technologies: Automated Patch Clamp and Optogenetics.

Here is how it works, using our city analogy:

1. The High-Speed Train (Automated Patch Clamp):
   Instead of the librarian sorting books one by one, imagine a high-speed train that can grab and sort 384 books (or neurons) all at once. This machine is fast and efficient, but it has a blind spot: it can't see the books' titles. It just grabs whatever is in the seat. So, it's fast, but it doesn't know which specific type of neuron it's holding.

2. The GPS Tag (Optogenetics):
   To solve the "blind spot" problem, the scientists genetically engineered special mice. They gave the specific "pain neurons" (the ones we want to study) a tiny, invisible GPS tag. In the real experiment, this tag is a light-sensitive protein called Channelrhodopsin.

   • Think of this like giving the "Pain Commuters" a special glowing badge that only lights up when you shine a blue flashlight on them.

3. The Magic Flashlight (The Combination):
   The scientists put the neurons on the high-speed train (the automated machine). Once the machine grabs a neuron, it shines a blue light on it.

   • If the neuron glows (responds to light): The machine knows, "Aha! This is a Pain Commuter (NaV1.8 or TRPV1 type)!"
   • If it doesn't glow: The machine knows, "This is a different type of commuter; let's ignore it for this specific test."

What Did They Find?

Using this "High-Speed Train with a GPS," the team was able to:

• Sort the crowd instantly: They could quickly identify and record from only the specific pain neurons they cared about, ignoring the rest.
• Test the brakes: They tested how these specific neurons reacted to different drugs. For example, they found that a specific drug (Suzetrigine) acts like a brake specifically on the "NaV1.8" pain neurons, slowing them down without stopping the whole city.
• Prove it works for heat too: They showed this same trick works for neurons that detect heat (TRPV1), proving the method is versatile.

Why Does This Matter?

Imagine you are trying to fix a traffic jam caused by a specific type of truck. Before, you had to stop every single car on the road to find the trucks, which took forever and caused more jams. Now, you have a system that instantly spots the trucks and lets you apply a solution just to them.

This new method allows scientists to:

• Work faster: They can test hundreds of potential painkillers in the time it used to take to test a few.
• Be more precise: They can design drugs that target only the pain signals, reducing side effects.
• Understand pain better: By isolating specific neuron types, we can finally understand exactly how different kinds of pain work.

In short, the authors built a smart, high-speed sorting machine that can instantly recognize the "pain neurons" in a crowd of thousands, paving the way for faster development of better, safer pain medications.

Technical Summary

1. Problem Statement

• Heterogeneity of DRG Neurons: Dorsal Root Ganglion (DRG) neurons are highly heterogeneous, expressing a complex mix of ion channels (e.g., multiple NaV subtypes like NaV1.3, 1.6, 1.7, 1.8, and 1.9). This makes it difficult to distinguish specific neuronal subtypes based solely on electrophysiological properties.
• Limitations of Current Methods:
  • Manual Patch Clamp: While it allows for cell identification via morphology or fluorescence, it is low-throughput, labor-intensive, and time-consuming, creating a bottleneck for drug screening.
  • Automated Patch Clamp (APC): Offers high-throughput recording (384-well format) but lacks the ability for the operator to visually identify specific cell subtypes within the heterogeneous population, leading to "unbiased" but non-specific data.
  • iPSC-Derived Neurons: While promising, these models do not yet fully recapitulate all DRG subtypes (e.g., reliable NaV1.8 expression remains challenging).
• The Gap: There is a critical need for a high-throughput method that can selectively record from genetically defined DRG subpopulations (specifically nociceptors expressing targets like NaV1.8 or TRPV1) to accelerate the development of non-opioid analgesics.

2. Methodology

The authors developed a hybrid approach combining Automated Planar Patch Clamp (APC) with Optogenetic Identification.

• Genetic Strategy:
  • Used Cre-LoxP system to generate transgenic mice.
  • NaV1.8 Line: NaV1.8-Cre mice crossed with Ai32 (Rosa26-CAG-ChR2-EYFP) mice. Channelrhodopsin-2 (ChR2) is expressed exclusively in NaV1.8-positive neurons.
  • TRPV1 Line: Trpv1-Cre mice crossed with Ai32 mice to target TRPV1-positive neurons.
• Cell Preparation:
  • Acute isolation of DRG neurons from 12–16 week old mice.
  • Enzymatic digestion (Collagenase IV, Papain, DNase I) followed by density gradient centrifugation to purify neurons.
  • Cells were resuspended and dispensed into 384-well plates for APC recording.
• Recording Protocol (NaV1.8 Study):
  • Platform: SyncroPatch 384 (Nanion Technologies).
  • Pharmacological Isolation:
    1. Baseline: Record total NaV currents.
    2. TTX Block: Apply 150 nM Tetrodotoxin (TTX) to block TTX-sensitive (TTX-S) currents, isolating TTX-resistant (TTX-R) currents.
    3. A-803467 Block: Apply 100 nM A-803467 (NaV1.8 selective blocker) in the presence of TTX to isolate non-NaV1.8 TTX-R currents.
  • Optogenetic Identification: After electrophysiological characterization, blue light pulses (460–480 nm) were applied via a 96-LED module to activate ChR2. Cells exhibiting light-induced inward currents were classified as NaV1.8-expressing.
• Data Analysis:
  • Applied strict inclusion criteria: Seal resistance $\ge$ 0.1 G$\Omega$, peak current > -50 pA, and specific kinetic filters to exclude NaV1.9-dominated slow currents.
  • Analyzed current density, voltage-dependence (activation/inactivation $V_{1/2}$), and kinetics.

3. Key Contributions

• Novel Workflow: Established the first high-throughput workflow that couples automated patch clamp with optogenetic cell-type identification, overcoming the "blindness" of APC in heterogeneous tissues.
• Selective Subtype Recording: Demonstrated the ability to specifically isolate and characterize electrophysiological properties of NaV1.8-expressing neurons and TRPV1-expressing neurons from a mixed DRG population without manual selection.
• Scalability: Proved that this method can be applied to different ion channel targets (NaV and TRPV) using the same genetic/optogenetic framework.

4. Key Results

• Efficiency: Approximately 70% of recorded cells exhibited light-induced currents, confirming successful optogenetic labeling and identification.
• Electrophysiological Characterization of NaV1.8 Neurons:
  • Current Composition: In identified NaV1.8 neurons, TTX-S currents comprised ~80% of total current, while TTX-R currents comprised ~25%. The A-803467-sensitive (NaV1.8 specific) component was ~11% of total current.
  • Voltage Dependence:
    • TTX-S currents activated/inactivated at more hyperpolarized potentials ($V_{1/2}$ activation $\approx$ -30 mV).
    • TTX-R and NaV1.8 currents were significantly depolarized relative to TTX-S (activation $V_{1/2}$ shifted by ~15 mV; inactivation $V_{1/2}$ shifted by ~11–20 mV).
    • NaV1.8 currents showed steeper inactivation slopes compared to TTX-S.
  • Kinetics: TTX-S currents inactivated significantly faster than TTX-R and NaV1.8 currents across all tested voltages (-30 to +10 mV).
• TRPV1 Validation:
  • Successfully recorded capsaicin-induced currents in TRPV1-Cre/ChR2 mice.
  • Confirmed specificity: Capsaicin induced inward currents (-77.8 pA/pF) which were suppressed by the TRPV1 blocker capsazepine.
  • Concordance: 100% concordance was observed between cells showing light-induced currents (ChR2+) and those showing capsaicin-sensitive currents.

5. Significance and Implications

• Drug Discovery Acceleration: This method enables high-throughput screening of novel analgesic compounds specifically targeting NaV1.8 or TRPV1 channels, addressing the current bottleneck in preclinical pain research.
• Precision Pharmacology: By isolating specific subtypes, researchers can better interpret pharmacological data, distinguishing between off-target effects on other NaV subtypes and true efficacy on the target subtype.
• Future Applications: The approach is modular and can be extended to other genetically defined DRG subtypes (e.g., specific peptidergic or non-peptidergic neurons) using existing Cre-driver mouse lines.
• Limitations: The study notes that acute isolation shears neuronal processes, potentially affecting spontaneous firing properties, and that the method relies on the availability of specific Cre-driver mouse lines.

In conclusion, Vanoye et al. present a robust, scalable platform that merges the throughput of automated electrophysiology with the specificity of optogenetics, offering a transformative tool for the study of nociceptor physiology and the development of targeted pain therapeutics.